Kirjojen hintavertailu. Mukana 11 699 587 kirjaa ja 12 kauppaa.

Kirjahaku

Etsi kirjoja tekijän nimen, kirjan nimen tai ISBN:n perusteella.

2 kirjaa tekijältä John Frederick Derr

Devil Tree

Devil Tree

John Frederick Derr

iUniverse
2005
pokkari
James Pharmaceutical Company (JPC) is on the verge of a colossal breakthrough in the world of pharmaceuticals: a cure for Alzheimer's disease. JPC has developed the formula, but cannot perfect the product due to side effects as well as a cash shortage. When the president of JPC discovers that an unknown yet trusted key employee has made a copy of a secret document outlining the cure, he calls in a favor from his old friend, Jean Paul Koenig, PhD. Jean Paul, or J. P., an expert in herbal pharmaceuticals, reluctantly agrees to get involved. Along the way, J. P. befriends a Japanese intelligence officer who has been trying to find a new product for a small innovative Japanese pharmaceutical company in Bandai, Japan. Together they evaluate the situation and work through deceit and violence as major international pharmaceutical companies fight for the highly coveted pharmaceutical, its raw material, and the rights to market it.
Devil Tree

Devil Tree

John Frederick Derr

iUniverse
2005
sidottu
James Pharmaceutical Company (JPC) is on the verge of a colossal breakthrough in the world of pharmaceuticals: a cure for Alzheimer's disease. JPC has developed the formula, but cannot perfect the product due to side effects as well as a cash shortage. When the president of JPC discovers that an unknown yet trusted key employee has made a copy of a secret document outlining the cure, he calls in a favor from his old friend, Jean Paul Koenig, PhD. Jean Paul, or J. P., an expert in herbal pharmaceuticals, reluctantly agrees to get involved. Along the way, J. P. befriends a Japanese intelligence officer who has been trying to find a new product for a small innovative Japanese pharmaceutical company in Bandai, Japan. Together they evaluate the situation and work through deceit and violence as major international pharmaceutical companies fight for the highly coveted pharmaceutical, its raw material, and the rights to market it.